Physician profile
Bradley D Root
NPI 1154312197
$3,115.80
in general payments reported to CMS, 2019-2025
30 companies · $646 in 2025
The $646 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $215 · 2021: $239 · 2022: $425 · 2023: $267 · 2024: $871 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,783.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $511.89 | 2022-2025 | Vyepti |
| Boston Scientific Corporation | $452.38 | 2019-2025 | Intracept, General - Pain Management |
| Abbvie INC. | $359.25 | 2021-2025 | Ubrelvy |
| Pfizer INC. | $307.12 | 2019-2025 | |
| Protega Pharmaceutials INC | $240.94 | 2024-2025 | Roxybond |
| Collegium Pharmaceutical, INC. | $196.32 | 2019-2025 | Belbuca |
| Averitas Pharma INC. | $190.94 | 2023-2025 | Qutenza |
| Biohaven Pharmaceutical Holding Company Ltd. | $96.78 | 2022 | |
| Indivior INC. | $96.21 | 2024-2025 | Sublocade |
| Saol Therapeutics INC. | $73.55 | 2020 | |
| Amgen INC. | $70.04 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $70.01 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $59.75 | 2023-2024 | Quviviq |
| Daiichi Sankyo INC. | $44.67 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.25 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $35.87 | 2019 | |
| Grt US Holding, INC. | $31.33 | 2021-2022 | |
| Axsome Therapeutics, INC. | $30.77 | 2024 | Sunosi |
| Medtronic, INC. | $26.55 | 2021-2023 | Intellis Adaptivestim |
| Shionogi INC | $25.37 | 2019 | |
| Relievant Medsystems, INC. | $21.81 | 2022-2023 | Intracept |
| Nevro Corp. | $18.55 | 2023 | Senza |
| Vertex Pharmaceuticals Incorporated | $17.63 | 2024 | |
| Medtronic USA, INC. | $15.98 | 2019 | |
| Biogen, INC. | $15.30 | 2019 | |
| Sentynl Therapeutics, INC. | $13.51 | 2019 | |
| Scilex Pharmaceuticals INC. | $13.11 | 2019 | |
| Lilly USA, LLC | $12.61 | 2020 | |
| Horizon Therapeutics Plc | $12.50 | 2019 | |
| Abbott Laboratories | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Root listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.